Black Diamond Therapeutics, Inc.
BDTX · Biological Products, (No Diagnostic Substances) · 57.3M shares · +14%/yr ↑ dilution · EDGAR filings ↗
Reference price $2.07 · est. market cap ~$119M — last insider sale, 2025-03-19 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical-stage oncology biotech whose reported profit is one-time/deal-driven, with underlying cash burn.
Strengths
- Liquidity — current ratio 8.4 (76th)
Risks
- Reported profit is one-time, not operational — per metrics
- Underlying cash burn — per metrics
- Clinical/commercial execution risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +14%/yr over 4y (dilution, book value/share -66%)
- Strong balance sheetStrong balance sheet — $129M cash & investments
- Notable holderHeld by 5 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, GOLDMAN SACHS GROUP INC, FMR LLC +2 more (as of 2026-03-31)
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
Key metrics
Return on equity
19.9%
Return on assets
15.6%
Current ratio
8.4×
Tangible book value
$112M
Cash & investments
$129M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-19 | Raman Prakash | Grant | 7.9K | $1.66 |
| 2026-06-19 | Behbahani Ali | Grant | 9.0K | $1.66 |
| 2026-03-20 | Raman Prakash | Grant | 6.1K | $2.15 |
| 2026-03-20 | Behbahani Ali | Grant | 6.9K | $2.15 |
| 2025-12-12 | Raman Prakash | Grant | 4.7K | $2.76 |
| 2025-12-12 | Behbahani Ali | Grant | 5.2K | $2.76 |
| 2025-09-19 | Raman Prakash | Grant | 3.8K | $3.35 |
| 2025-09-19 | Behbahani Ali | Grant | 4.3K | $3.35 |
| 2025-06-20 | Raman Prakash | Grant | 5.5K | $2.33 |
| 2025-06-20 | Behbahani Ali | Grant | 6.2K | $2.33 |
| 2025-03-21 | Raman Prakash | Grant | 6.8K | $1.88 |
| 2025-03-21 | Behbahani Ali | Grant | 7.6K | $1.88 |
| 2025-03-19 | BIOTECH GROWTH N V | Sell | 1.0M | $2.07 |
| 2025-03-19 | BIOTECH GROWTH N V | Sell | 300K | $1.94 |
| 2025-03-19 | BIOTECH GROWTH N V | Sell | 1.0M | $2.31 |
| 2025-03-19 | BIOTECH GROWTH N V | Sell | 2.0M | $2.00 |
| 2025-03-19 | BIOTECH GROWTH N V | Sell | 400K | $2.09 |
| 2025-03-19 | BIOTECH GROWTH N V | Sell | 584K | $1.95 |
| 2025-03-19 | BIOTECH GROWTH N V | Sell | 500K | $2.12 |
| 2025-01-30 | Velleca Mark A. | Grant | 75K | — |
| 2025-01-30 | Yurasov Sergey | Grant | 75K | — |
| 2025-01-30 | Buck Elizabeth | Grant | 75K | — |
| 2025-01-30 | Jones Erika | Grant | 75K | — |
| 2025-01-30 | Hatzis-Schoch Brent | Grant | 75K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07326566 ↗ | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Glioblastoma (GBM), Newly Diagnosed Glioblastoma | PHASE2 | Recruiting | 2028-11-01 |
| NCT05256290 ↗ | Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer | PHASE1/PHASE2 | Active Not Recruiting | 2025-11-03 |
| NCT04209465 ↗ | A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. Solid Tumor | PHASE1 | Terminated | 2022-09-02 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-21 | 2026-05-21 | 0001104659-26-065254 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001701541-26-000017 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001701541-26-000015 ↗ |
| 10-K | 2026-03-16 | 2025-12-31 | 0001701541-26-000009 ↗ |
| 8-K | 2026-03-16 | 2026-03-16 | 0001701541-26-000008 ↗ |
| 8-K | 2025-12-03 | 2025-12-03 | 0001104659-25-117975 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001701541-25-000038 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001701541-25-000039 ↗ |
| 8-K | 2025-08-07 | 2025-08-07 | 0001701541-25-000029 ↗ |
| 10-Q | 2025-08-07 | 2025-06-30 | 0001701541-25-000030 ↗ |
| 8-K | 2025-06-12 | 2025-06-12 | 0001104659-25-058893 ↗ |
| 10-Q | 2025-05-12 | 2025-03-31 | 0001701541-25-000022 ↗ |